Sign in with Google
bullish
3SBio Inc (1530 HK): Core Biopharmaceutical Portfolio On A Double-Digit Growth Path
Tina has highlighted this Insight as a Top Pick
543 Views17 Jun 2022 10:31
SUMMARY
- 3SBio Inc (1530 HK)'s core products have dominant market share in their respective therapeutic areas, lending a favorable financial profile to the company to fund its R&D and commercialization efforts.
- Flagship drug, TPIAO remained resilient to the COVID-19 and clocked a revenue CAGR of 32% during 2016–2021. Low penetration of TPIAO’s targeted indications leaves further room for its growth.
- Haircare product Mandi has high market share of 70%+ and clocked 64% y/y revenue growth in 2021. 3SBio aims to launch Mandi foam, which will further sharpen its competitive edge.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Renesas Electronics Block - Well Flagged, Clean up but Momentum Isn’t Great
- CATL (3750 HK) H-Share IPO: Fast Entry to Global Indices Is Touch & Go
- HSTECH Index Rebalance Preview: BYD (1211 HK) Could Replace China Literature (772 HK); Huge Trade
- CATL: Key Highlights in 1Q 2025 and PHIP Updates on Hong Kong Listing
- CATL A/H Listing - High Quality, Large Size Make It Unavoidable but Needs a Discount
Top Unpaywalled Insights
More »- Curator's Cut: "Bubble" Tea, Japan M&A 🍿and TSMC from Different Lenses
- The Coming Global Trade Re-Ordering
- The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
x